New data presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions suggests the ProGlide (PG) vascular closure device (VCDs) is superior to Prostar XL (PS) for transcatheter aortic valve replacement (TAVR).
The BRAVO-3 trial stratified 802 patients undergoing transfemoral TAVR according to the type of VCD used and examined the 30-day incidence of major or minor vascular complications, major bleeding (Bleeding Academic Research Consortium category ≥3b), acute kidney injury (AKI) and major adverse cardiac and cerebrovascular events (MACCE). Major vascular events were defined as a blood transfusion ≥4 units and unplanned interventions for closure or complications leading to death or end organ damage.
In total, 746 (93%) patients were treated with PG (n= 394) or PS (n= 352) VCDs, without significant differences in successful deployment rate (94.2% vs 91.2%; P=.20).
PG was associated with a lower rate of AKI (17% vs 25%; adjusted OR [aOR] 0.61; 95% CI 0.40-0.90; P=.01) and a significantly lower incidence of major or minor vascular complications, compared to PS (15% vs 24%; aOR 0.54; 95% CI 0.37-0.80; P<.01 pg was also associated with a shorter length of hospital stay days>